COVID et Neuroleptiques : Lien Protecteur ?

Abstract

Since December 2019, a 2019 coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan and subsequently becomes a global epidemic. The virus can spread and be transmitted from one infected person to another directly or indirectly. Symptomatology varies from asymptomatic to more severe forms associated with complications such as acute respiratory distress syndrome, and in some cases can lead to death. Several diagnostic techniques have been developed and put on the market, including RTPCR which represents the reference method due to its sensitivity and specificity. Preventive measures are necessary, both individually (hand hygiene) and collectively (vaccination). However, no specific treatment to cure the infection is available to date. the hypothesis of a relationship between antipsychotic drugs and Covid-19 disease has been discussed in several studies, because numerous data have shown that they support and prove the role of these drugs in protection against infection by the latter and in the prevention of its severe and dangerous complications, and therefore antipsychotics can be a new treatment for Covid-19. These data have been confirmed by randomized trials, which are the result of the observation of the low incidence of Covid-19 and the low presence of severe complications in patients with psychological disorders at the level of. the psychiatry department. According to these first results which must still be reproduced on larger cohorts, which already suggest the possibility of a repositioning of neuroleptics..., justifying the possibility of considering them as a new treatment for Covid-19, and of studying the mechanism of their action in this role.